Business Context and Reporting Period
Scilex Holding Company reported preliminary, unaudited operating results for the one month ended October 31, 2023, and year-to-date through October 31, 2023. The filing primarily addresses sales of ZTlido and total products. The company’s independent auditor has not reviewed or audited the estimates, and final results may differ materially.
Key Financial and Operating Metrics
| Metric | October 2023 | Year-to-date through October 31, 2023 | Comparable period |
|---|---|---|---|
| ZTlido gross sales | $14.5 million–$15.5 million | $110.0 million–$120.0 million | $74.8 million in YTD 2022; growth of 47%–60% |
| ZTlido net sales | $4.0 million–$5.0 million | $35.0 million–$40.0 million | $30.4 million in YTD 2022; growth of 15%–32% |
| Total product gross sales | $15.5 million–$16.5 million | $115.0 million–$125.0 million | $74.8 million in YTD 2022; growth of 54%–67% |
| Total product net sales | $4.0 million–$5.0 million | $35.0 million–$40.0 million | $30.4 million in YTD 2022; growth of 15%–32% |
The filing does not provide clear values for profit, operating margins, cash flow, cash balances, debt, liquidity, or other balance-sheet metrics.
Material Changes Versus the Prior Comparable Period
- ZTlido year-to-date gross sales increased an estimated 47%–60% versus the first ten months of 2022.
- ZTlido year-to-date net sales increased an estimated 15%–32% versus the first ten months of 2022.
- Total product year-to-date gross sales increased an estimated 54%–67% versus the first ten months of 2022.
- Total product year-to-date net sales increased an estimated 15%–32% versus the first ten months of 2022.
- ZTlido’s full-year 2022 gross sales were $96.0 million and net sales were $38.0 million; the filing does not provide a 2023 full-year forecast.
Guidance, Outlook, Risks, and Unusual Items
- The reported figures are preliminary estimates based on currently available information, not formal audited results or full-year guidance.
- Management cautions that the company has not completed its review and that actual results may differ materially from, or fall outside, the stated ranges.
- The filing does not provide specific commentary on profitability, cash needs, debt, liquidity, contingencies, or other material risks.
- Gross sales and net sales differ materially; investors should not treat gross sales as reported revenue without reviewing the company’s final financial statements and revenue recognition disclosures.
- The Item 2.02 information is furnished rather than filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.
Important Facts for Investors to Verify
- Final October and year-to-date results when reported in subsequent filings or earnings materials.
- Whether the estimated sales ranges translate into comparable growth in recognized revenue after deductions from gross sales.
- Gross margin, operating expenses, net loss or income, cash flow, cash balance, debt, and liquidity at the final reporting date.
- The drivers of the substantial difference between gross sales and net sales.
- Any updated full-year outlook, financing requirements, or contingencies not addressed in this 8-K.